PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 25,891 followers.

RT @Dr_Ivanoncologo: PD-1 inhibitors, including #pembrolizumab and #nivolumab, have shown early efficacy and safety for advanced/metastatic…

RT @Dr_Ivanoncologo: PD-1 inhibitors, including #pembrolizumab and #nivolumab, have shown early efficacy and safety for advanced/metastatic…

RT @Dr_Ivanoncologo: PD-1 inhibitors, including #pembrolizumab and #nivolumab, have shown early efficacy and safety for advanced/metastatic…

RT @Dr_Ivanoncologo: PD-1 inhibitors, including #pembrolizumab and #nivolumab, have shown early efficacy and safety for advanced/metastatic…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.